Introduction {#s1}
============

Sudden cardiac death (SCD) is a leading cause of death in adults in the Western world [@pone.0057216-Myerburg1]. The overwhelming majority (∼80%) of SCDs in adults are caused by the sequelae of coronary artery disease, namely myocardial ischemia or acute myocardial infarction (MI) [@pone.0057216-Huikuri1]. While the risk of VF is known to have a genetic component, the underlying genetic factors are yet largely unknown [@pone.0057216-Dekker1]--[@pone.0057216-Kaikkonen1].

Electrocardiographic indices of conduction and repolarization are considered important quantifiable intermediate phenotypes for arrhythmia risk [@pone.0057216-Kolder1]. In support of this concept, ECG indices measured during the acute phase of ST elevation MI (STEMI) were associated with risk of ensuing VF [@pone.0057216-Lemmert1]. A number of studies have demonstrated that heart rate, PR interval, QRS duration and QTc interval are heritable traits [@pone.0057216-Havlik1]--[@pone.0057216-Russell1] and over the last years genome-wide association studies (GWAS) in large samples of the general population have uncovered several common single nucleotide polymorphisms (SNPs) affecting these ECG traits [@pone.0057216-Chambers1]--[@pone.0057216-Eijgelsheim1].

The objective of this study was to assess whether SNPs, previously associated with heart rate and ECG indices of conduction and repolarization in GWAS in the general population, modulate ECG indices and risk of VF during acute STEMI. Specifically, we hypothesized that ECG-related SNPs modulate heart rate and ECG conduction and repolarization intervals in the setting of acute STEMI and thereby modulate (and predict) the risk of VF in this condition.

Methods {#s2}
=======

Ethics statement {#s2a}
----------------

The study protocol was approved by the Institutional Review Board of the Academic Medical Center, University of Amsterdam, and was conducted according to the principles of the Declaration of Helsinki. All participants gave written informed consent.

Study samples {#s2b}
-------------

The study population consisted of participants of the **A**rrhythmia **G**enetics in the **NE**therland**S** (AGNES) case-control study which has been described in detail previously [@pone.0057216-Dekker1], [@pone.0057216-Bezzina1]. In brief, the AGNES study enrols patients with a first acute STEMI. Cases are defined as patients who were successfully resuscitated after documented VF that occurred between the onset of symptoms and coronary intervention. Controls are defined as acute STEMI patients who did not develop VF. Patients with a previous MI or major co-morbidity were excluded. All individuals studied were of self-declared European ancestry.

Measurement of ECG indices {#s2c}
--------------------------

The first recorded ECG that was acquired during STEMI and before reperfusion treatment was used for analysis. For cases, both ECGs acquired pre-VF as well as post-VF were included. ECGs of insufficient quality (due to e.g. baseline drift or missing leads) and ECGs with rhythms other than sinus rhythm or atrial fibrillation (AF) were excluded. Patients with AF (n = 23) were excluded for the analyses of PR interval, but included for the other ECG indices. All ECGs were digitized at 400 dpi (giving a spatial resolution 0.064 mm or 1.6 ms / pixel on an ECG traced at 25 mm / sec). Calibrated measurements were performed on-screen after 4 times enlargement of the digitized ECGs in ImageJ (National Institutes of Health, Bethesda, Maryland, <http://rsb.info.nih.gov/ij/>). RR-interval (heart rate) was measured from the ECG. PR interval was measured from the onset of the P-wave to the onset of ventricular depolarization. QRS duration was measured from the onset of ventricular depolarization to the J point. QTc interval was measured using the tangent method [@pone.0057216-Postema1]. Lead II was used when the T wave was of sufficient amplitude to warrant QT measurement, otherwise leads V5 or V2 were used. QT was corrected for heart rate (QTc) using Fridericia\'s formula (QTc  =  QT / (cube root (RR)). ST deviation was calculated as the sum of all ST deviation from baseline at 60 ms after the J point in all 12 leads. ST deviation was not reported if individual leads were disconnected or in patients with left bundle branch block. The mean of three consecutive beats wherever possible was measured for all parameters and used in subsequent analyses. Patients with AV block, PR interval ≥ 200 ms or QRS duration ≥ 120 ms were excluded from the ECG analyses involving the continuous endpoints PR interval, QRS duration and QTc interval. For PR interval and QRS duration, additional dichotomous endpoints were assessed i.e. PR interval ≥ 200 ms and QRS duration ≥ 120 ms. Patients with AV block were included in the dichotomized PR interval endpoint as PR \> 200 ms.

Selection of SNPs and Genotyping {#s2d}
--------------------------------

We inspected the published GWAS concerning heart rate and ECG indices of conduction and repolarization and identified SNPs reported to be associated with these parameters at genome-wide significant *P*-values (*P*\<5×10^−8^) [@pone.0057216-Peer1]. In case of high linkage disequilibrium (r2≥0.75) between identified SNPs, only a single SNP, capturing the maximum amount of variation present in the correlated SNPs, was selected for our analysis. This was the case for SNPs at the *SCN10A*, *SCN5A*, *KCNH2*, *KCNQ1*, *CNOT1*, *ARHGAP24*, *NOS1AP*, *CDKN1A, GJA1* and *MYH6* loci. A total of 65 SNPs were identified in this way. Genotypes for these SNPs were either obtained by direct genotyping (Illumina610 Quad genotyping array) or were estimated by imputation using HapMap build 36 as the reference panel. Details on genotyping and imputation in the AGNES sample have been described previously [@pone.0057216-Bezzina1].

Statistical Analysis {#s2e}
--------------------

We tested differences between cases and controls in continuous variables with an independent sample t-test, or the Mann-Whitney U test when the data was not normally distributed. We compared differences in the percentages of categorical variables with the Pearson χ^2^ test. We used linear regression modelling in association analyses of continuous endpoints and logistic regression modelling for association analyses of dichotomous endpoints (VF, PR≥200 ms and QRS≥120 ms). In all models, we assumed an additive genetic model and corrected for age, sex and the culprit artery (harbouring the occluding lesion) [@pone.0057216-Lemmert1] as well as the possible interaction between culprit artery and the SNPs. The occurrence of the latter was first tested using a Wald test.

Our analysis plan had a two-stage design. In the first stage, we tested for association of the selected SNPs with the corresponding ECG parameter during STEMI. In the second stage, we selected those SNPs with a (suggestive) significant effect on the ECG parameter and analyzed their effect on the occurrence of VF.

The Bonferroni thresholds for statistical significance were *P*≤0.0002 for the first stage (corrected for two tests per SNP and six outcomes: HR, QTc, PQ, PQ≥200, QRS and QRS≥120, resulting in a total of 210 tests) and *P*≤(0.05/number of SNPs carried over from stage 1) for the second stage. For both stages, *P*-values between the Bonferroni threshold and 0.05 were considered as a suggestive trend.

Power and detectable effects {#s2f}
----------------------------

Given the observed standard deviations in our study population for heart rate and the ECG indices, the reported effects of the identified SNPs would result in effect sizes ≤ 0.2 SD. With the present range in sample sizes (417 -- 515), the power to detect an effect size of 0.2 of a SNP with a minor allele frequency (MAF) ranging from 0.05 to 0.5 would range from 1 to 31% for a two-sided p-value of 0.0002 (Bonferroni threshold) and from 24 -- 90% for a two-sided p-value of 0.05 (suggestive trend). The present study, therefore, lacks the power to significantly detect effect sizes as found in the general population (from the GWAs). However, given the fact that our heart rate and ECG indices were measured in patients experiencing a STEMI, we hypothesized that the SNP effects might be markedly increased in this sensitized population.

Given the present range in sample sizes, the study had 80% power to detect effect sizes of 0.7 to 0.3 (± 5% explained variance) for the quantitative traits at MAFs ranging from 0.05 to 0.5 assuming an additive genetic model and a two-sided significance threshold of 0.0002 (Stage 1). For PR interval with an overall standard deviation of 20 ms, for example, this translates into detectable allele effects (beta) ranging from 14 to 6 ms. For the dichotomized endpoints, we were able to detect odds ratio\'s ranging from 2.3 to 1.6 (Stage 1, α = 0.0002).

Results {#s3}
=======

VF and ischemic ECG indices {#s3a}
---------------------------

Baseline characteristics of the study population are shown in [**Table 1**](#pone-0057216-t001){ref-type="table"}. As reported previously [@pone.0057216-Dekker1], [@pone.0057216-Bezzina1], AGNES cases had a lower prevalence of diabetes mellitus and hypercholesterolemia, and lower mean body mass index (BMI) than AGNES controls. AGNES cases more often had a family history of sudden cardiac death as compared to controls.

10.1371/journal.pone.0057216.t001

###### Baseline characteristics of the AGNES case-control set.

![](pone.0057216.t001){#pone-0057216-t001-1}

  Characteristic                            N\*                  Total                       Cases                     Controls             *P* ^‡^
  ----------------------------------- --------------- ---------------------------- ------------------------- ----------------------------- ----------
  Sex (male)                                                   783 (80.6)                 412 (80.0)                  371 (81.2)             0.685
  Mean age at myocardial infarction                             56.4±11                    55.9±11.2                  56.9± 10.8             0.174
  Family history of sudden death       909, 459, 450           291 (32.0)                 174 (37.9)                  117 (26.0)            \<0.0001
  CVD risk factors                                                                                                                         
  Current smoking                      914, 473, 441           565 (61.8)                 303 (64.1)                  262 (59.4)             0.1531
  Diabetes mellitus                    893, 462, 431            62 (6.9)                   21 (4.6)                    41 (9.5)              0.004
  Hypertension                                                 294 (30.2)                 149 (28.9)                  145 (31.7)             0.3633
  Hypercholesterolemia                                         297 (30.6)                 127 (24.7)                  170 (37.2)            \<0.0001
  Body mass index (BMI, kg/m^2^)       879, 439, 440            26.5±3.9                   26.1±3.8                    26.9±4.0              0.0042
  Peak CK-MB                           735, 337, 398          227 \[294\]                 241 \[354\]                 215 \[247\]            0.006
  Ischemic ECG                                                                                                                             
  RR interval (ms)                     453, 214, 239            807±204                     743±188                     864±203             \<0.0001
  ST segment deviation (mm)            474, 188, 286   15 [@pone.0057216-Arking1]   20 [@pone.0057216-Cho1]   13 [@pone.0057216-Pfeufer1]   \<0.0001
  PR interval (ms)                     417, 195, 222             157±20                     158±19                      157±20               0.358
  QRS duration (ms)                    452, 214, 238             93±13                       93±14                       93±13               0.860
  QTc interval (ms)                    424, 200, 224             410±35                     415±37                      405±31               0.003
  PR≥200 ms                            515, 249, 266           57 (11.0)                   32 (12.7)                   25 (9.5)              0.153
  QRS≥120 ms                           509, 252, 257           57 (11.2)                   38 (15.1)                   19 (7.4)              0.007
  Culprit artery                       811, 430, 381                                                                                       
  RCA                                                          220 (27.1)                 109 (25.3)                  111 (29.1)           
  LAD                                                          475 (58.6)                 260 (60.5)                  215 (56.4)             0.202
  LCX                                                          116 (14.3)                  61 (14.2)                   55 (14.4)           

CK-MB, creatine kinase-MB; LAD, left anterior descending artery; LCX, left circumflex artery; RCA, right coronary artery. \*In case of missing values, the sample sizes of the total, case and control sets (total, case, control) for which information was available are given. ^†^ Normally distributed continuous variables are presented as mean ± SD or as Median \[interquartile range\] otherwise. Categorical variables data are presented as number (%). ‡ *P* value for comparison of cases and controls using independent t-test, Mann-Whitney test, or chi-square test where appropriate.

STEMI ECGs of sufficient quality were available for 599 patients. Of these, 79 (13%) patients had QRS≥120 ms, and 85 (14%) patients had a PR≥200 ms or higher degree AV block; several patients had a combination of these ECG abnormalities. Because of these exclusions and missing values, the number of available observations varied between 417 and 515. VF cases showed, on average, a shorter RR interval, a longer QTc interval, a greater ST segment deviation and more often prolongation of the QRS interval(≥120 ms) as compared to controls ([**Table 1**](#pone-0057216-t001){ref-type="table"}). Location of the culprit coronary lesion modified the effect of QRS duration and QTc interval on risk of VF ([**Table 2**](#pone-0057216-t002){ref-type="table"}). For instance, QRS duration was more prolonged in cases compared to controls only among patients with a left circumflex artery (LCX) occlusion (*P* ~interaction~ = 0.002). QTc-interval tended to be more prolonged among patients with left anterior descending artery (LAD) or LCX occlusion (*P* ~interaction~ = 0.026).

10.1371/journal.pone.0057216.t002

###### ECG characteristics of AGNES cases and controls according to the artery harbouring the stenotic lesion.

![](pone.0057216.t002){#pone-0057216-t002-2}

                  Culprit artery   Cases (N)   Mean±SD   Controls (N)   Mean±SD   *P* value[\*](#nt103){ref-type="table-fn"}   Interaction *P* value
  -------------- ---------------- ----------- --------- -------------- --------- -------------------------------------------- -----------------------
  RR interval          LAD            130      728±170       124        822±180                    \<0.0001                   
                       LCX            25       751±185        35        866±213                     0.047                              0.974
                       RCA            43       791±230        70        944±214                     0.001                     
  PR interval          LAD            117      158±19        112        159±18                      0.879                     
                       LCX            24       150±17         33        151±19                      0.647                              0.423
                       RCA            39       163±20         67        157±22                      0.168                     
  QRS duration         LAD            130       93±13        123         91±13                      0.288                     
                       LCX            25        98±11         35         88±9                       0.002                              0.002
                       RCA            43        94±16         70         98±12                      0.134                     
  QTc interval         LAD            120      422±37        113        413±28                      0.036                     
                       LCX            24       415±28         33        391±30                      0.020                              0.026
                       RCA            40       399±38         68        399±35                      0.939                     

LAD, left anterior descending artery; LCX, left circumflex artery; RCA, right coronary artery

*P* value of comparison between cases and controls using a logistic regression model adjusted for age and sex. (All patients with AV block or PR≥200 ms or QRS≥120 ms & AF are excluded)

ECG candidate SNPs and STEMI ECG indices (Stage 1) {#s3b}
--------------------------------------------------

None of the 65 SNPs tested displayed an association with the corresponding ECG trait that passed the Bonferroni-corrected significance threshold of *P*≤0.0002, nor showed an interaction with culprit artery. Eight SNPs displayed a trend (0.0002\<*P*\<0.05) in association with STEMI ECG indices ([**Table 3**](#pone-0057216-t003){ref-type="table"}). Regarding the continuous ECG outcomes, SNPs rs223116 and rs281868 showed a trend for association with RR interval (*P* = 0.004 and 0.014, respectively) and SNP rs6795970 showed a trend for association with PR interval (*P* = 0.004). SNPs rs1886512 and rs883079 showed a trend for association with QRS duration (*P* = 0.010 and 0.007, respectively). SNPs rs17779747 and rs8049607 showed a trend for association with QTc interval (*P* = 0.004 and 0.036, respectively). Regarding the dichotomized ECG endpoints, the C-allele of SNP rs11708996 showed a trend for association with PR≥200 ms with an odds ratio of 2.39 (95% CI: 1.33 -- 4.30; *P* = 0.004). None of the QRS SNPs showed any significant association with QRS≥120 ms.

10.1371/journal.pone.0057216.t003

###### Association analysis of SNPs with ECG indices of conduction and repolarization during myocardial ischemia.

![](pone.0057216.t003){#pone-0057216-t003-3}

  SNP           End point   Coded/Non Coded Allele   GWAS Effect^\*^   Minor Allele (Frequency)   Beta (SE)^†^   *P* value   *P* value Interaction               Gene
  ------------ ----------- ------------------------ ----------------- -------------------------- -------------- ----------- ----------------------- -------------------------------
  RR SNPs                                                                                                                                           
  rs11154022       RR                A/G                   Inc                 A (0.33)            6.5 (14.9)      0.664             0.975                 *8 kb from GJA1*
  rs12666989       RR                C/G                   Dec                 C (0.20)           −10.7 (17.6)     0.543             0.175                      *UFSP1*
  rs12731740       RR                T/C                   Inc                 T (0.12)           10.3 (22.3)      0.646             0.277               *CD3-MIR29C-MIR29B2*
  rs17287293       RR                G/A                   Inc                 G (0.14)           22.6 (19.7)      0.273             0.128                   *SOX5-BCAT1*
  rs174547         RR                C/T                   Dec                 C (0.31)           −11.7 (15.0)     0.438             0.343                      *FADS1*
  rs223116         RR                A/G                   Dec                 A (0.24)           −45.6 (15.9)     0.004             0.461              *THTPA-NGDN-ZFHX2-MYH7*
  rs2745967        RR                G/A                   Inc                 G (0.38)           −1.2 (14.1)      0.932             0.168                   *CD34-PLXNA2*
  rs281868         RR                G/A                   Dec                 A (0.49)           −33.8 (13.8)     0.014             0.061                     *SLC35F1*
  rs314370         RR                C/T                   Dec                 C (0.20)           −5.5 (17.4)      0.751             0.197                     *SLC12A9*
  rs452036         RR                A/G                   Dec                 A (0.39)           −10.4 (14.5)     0.472             0.823                      *MYH6*
  rs885389         RR                A/G                   Dec                 A (0.37)           −17.2 (14.7)     0.243             0.571                     *GPR133*
  rs9398652        RR                A/C                   Dec                 A (0.12)           −9.2 (21.9)      0.674             0.292                    *GJA1-HSF2*
  PR SNPs                                                                                                                                           
  rs11047543       PR                A/G                   Dec                 A (0.14)           −1.97 (1.94)     0.312             0.696                      *SOX5*
  rs11708996       PR                C/G                   Inc                 C (0.16)           −0.64 (2.11)     0.763             0.722                      *SCN5A*
  rs11897119       PR                C/T                   Inc                 C (0.38)           0.41 (1.42)      0.775             0.407                      *MEIS1*
  rs1896312        PR                C/T                   Inc                 C (0.29)           0.37 (1.49)      0.807             0.399                    *TBX5-TBX3*
  rs251253         PR                C/T                   Dec                 C (0.41)           −1.59 (1.37)     0.248             0.744                     *NKX2-5*
  rs3807989        PR                A/G                   Inc                 A (0.42)           0.17 (1.42)      0.904             0.170                    *CAV1-CAV2*
  rs3825214        PR                G/A                   Inc                 G (0.20)           −0.16 (1.74)     0.925             0.766                      *TBX5*
  rs4944092        PR                G/A                   Dec                 G (0.33)           −0.74 (1.48)     0.616             0.046                      *WNT11*
  rs6795970        PR                A/G                   Inc                 A (0.39)           4.06 (1.42)      0.004             0.031                     *SCN10A*
  rs7660702        PR                T/C                   Inc                 C (0.30)           −0.04 (1.42)     0.979             0.462                    *ARHGAP24*
  QRS SNPs                                                                                                                                          
  rs10850409       QRS               A/G                   Dec                 A (0.25)           −0.39 (0.98)     0.696             0.380                      *TBX3*
  rs10865879       QRS               T/C                   Inc                 C (0.25)           −0.45 (1.07)     0.671             0.792                   *SCN5A/EXOG*
  rs11153730       QRS               C/T                   Inc                 T (0.49)           −0.72 (0.87)     0.408             0.383           *C6orf204-SLC35F1-PLN-BRD7P3*
  rs11708996       QRS               C/G                   Inc                 C (0.16)           0.94 (1.37)      0.493             0.232                      *SCN5A*
  rs11710077       QRS               T/A                   Dec                 T (0.18)           0.59 (1.12)      0.596             0.517                      *SCN5A*
  rs11848785       QRS               G/A                   Dec                 G (0.27)           −0.34 (1.05)     0.743             0.756                     *SIPA1L1*
  rs13165478       QRS               A/G                   Dec                 A (0.37)           −1.45 (0.91)     0.115             0.559                  *HAND1-SAP30L*
  rs1321311        QRS               A/C                   Inc                 A (0.24)           −0.43 (1.08)     0.691             0.858                     *CDKN1A*
  rs1362212        QRS               A/G                   Inc                 A (0.16)           0.65 (1.29)      0.616             0.834                      *TBX20*
  rs17020136       QRS               C/T                   Inc                 C (0.21)           0.24 (1.08)      0.827             0.251                  *HEATR5B-STRN*
  rs1733724        QRS               A/G                   Inc                 A (0.27)           −0.51 (1.03)     0.621             0.274                      *DKK1*
  rs17391905       QRS               G/T                   Dec                 G (0.02)           −2.68 (3.13)     0.392             0.978           *C1orf185-RNF11-CDKN2C-FAF1*
  rs17608766       QRS               C/T                   Inc                 C (0.13)           1.31 (1.31)      0.320             0.453                      *GOSR2*
  rs1886512        QRS               A/T                   Dec                 A (0.37)           −2.39 (0.92)     0.010             0.880                      *KLF12*
  rs2051211        QRS               G/A                   Dec                 G (0.26)           −0.35 (1.03)     0.734             0.271                      *EXOG*
  rs2242285        QRS               A/G                   Inc                 A (0.43)           −0.24 (0.87)     0.784             0.888                 *LRIG1-SLC25A26*
  rs4074536        QRS               C/T                   Dec                 C (0.32)           1.19 (0.99)      0.232             0.749                      *CASQ2*
  rs4687718        QRS               A/G                   Dec                 A (0.12)           1.70 (1.34)      0.207             0.487                *TKT-PRKCD-CACNA1D*
  rs6795970        QRS               A/G                   Inc                 A (0.39)           0.52 (0.91)      0.569             0.326                     *SCN10A*
  rs7342028        QRS               T/G                   Inc                 T (0.25)           1.89 (1.03)      0.068             0.051                      *VTI1A*
  rs7562790        QRS               G/T                   Inc                 G (0.43)           −0.22 (0.91)     0.812             0.529                      *CRIM1*
  rs7784776        QRS               G/A                   Inc                 G (0.41)           −0.82 (0.93)     0.383             0.265                     *IGFBP3*
  rs883079         QRS               C/T                   Inc                 C (0.26)           2.77 (1.02)      0.007             0.147                      *TBX5*
  rs9436640        QRS               G/T                   Dec                 G (0.48)           −0.68 (0.89)     0.445             0.278                      *NFIA*
  QRS SNPs                                                                                                                                          
  rs9851724        QRS               C/T                   Dec                 C (0.35)           −1.25 (0.92)     0.177             0.527                     *SCN10A*
  rs991014         QRS               T/C                   Inc                 T (0.43)           −0.40 (0.91)     0.665             0.427                     *SETBP1*
  rs9912468        QRS               G/C                   Inc                 G (0.40)           0.28 (0.96)      0.770             0.511                      *PRKCA*
  QTc SNPs                                                                                                                                          
  rs10919071       QTc               A/G                   Inc                 G (0.11)           −0.01 (2.09)     0.997             0.774                     *ATP1B1*
  rs11970286       QTc               T/C                   Inc                 T (0.47)           0.13 (2.31)      0.954             0.996                       *PLN*
  rs12029454       QTc               A/G                   Inc                 A (0.14)           4.74 (3.20)      0.139             0.439                     *NOS1AP*
  rs12053903       QTc               C/T                   Dec                 C (0.33)           −4.13 (2.55)     0.106             0.911                      *SCN5A*
  rs12143842       QTc               T/C                   Inc                 T (0.24)           3.47 (2.69)      0.197             0.874                     *NOS1AP*
  rs12210810       QTc               C/G                   Dec                 C (0.04)           1.34 (5.33)      0.801             0.590                       *PLN*
  rs12296050       QTc               T/C                   Inc                 T (0.18)           0.19 (2.98)      0.948             0.914                      *KCNQ1*
  rs16857031       QTc               G/C                   Inc                 G (0.14)           6.18 (3.28)      0.060             0.571                     *NOS1AP*
  rs17779747       QTc               T/G                   Dec                 T (0.34)           −7.36 (2.52)     0.004             0.811                      *KCNJ2*
  rs1805128        QTc               A/G                   Inc                 T (0.05)           8.69 (5.56)      0.119             0.509                      *KCNE1*
  rs2074238        QTc               T/C                   Dec                 T (0.05)           −3.30 (6.68)     0.622             0.136                      *KCNQ1*
  rs2074518        QTc               T/C                   Dec                 T (0.49)           −1.13 (2.37)     0.633             0.683                      *LIG3*
  rs2968863        QTc               T/C                   Dec                 T (0.26)           −1.93 (2.84)     0.499             0.266                      *KCNH2*
  rs37062          QTc               G/A                   Dec                 G (0.23)           2.25 (2.84)      0.429             0.359                      *CNOT1*
  rs4657178        QTc               T/C                   Inc                 T (0.25)           3.78 (2.71)      0.165             0.543                     *NOS1AP*
  rs4725982        QTc               T/C                   Inc                 T (0.19)           0.71 (3.11)      0.819             0.674                      *KCNH2*
  rs8049607        QTc               T/C                   Inc                 C (0.49)           5.02 (2.39)      0.036             0.145                      *LITAF*
  rs846111         QTc               C/C                   Inc                 C (0.29)           0.70 (2.84)      0.806             0.056                     *RNF207*

SE, Standard Error \* Direction of effect estimate per copy coded allele; Inc, Increasing effect; Dec, Decreasing effect; data from previous GWA studies † Effect estimate is given per copy of the coded allele adjusted for age, sex and culprit artery (all patients with AV block or PR ≥ 200 ms or QRS ≥ 120 ms are excluded).

STEMI ECG SNPs and risk of VF (Stage 2) {#s3c}
---------------------------------------

We next tested the eight SNPs from Stage 1 showing a trend for association with the ECG parameters for association with VF. Of these eight, none passed the Bonferroni-corrected significance threshold (*P*≤0.0063) for association with risk of VF during STEMI. However, two SNPs, namely rs6795970 and rs17779747, were nominally associated with VF (*P* = 0.009 and 0.026, respectively) independent of the culprit artery. Another SNP, rs223116 displayed a nominal association with VF in patients with an occlusion in the LCX (*P* = 0.039) or RCA (*P* = 0.037) only ([**Table 4**](#pone-0057216-t004){ref-type="table"}).

10.1371/journal.pone.0057216.t004

###### Association analysis of SNPs with VF in AGNES cases versus AGNES controls.

![](pone.0057216.t004){#pone-0057216-t004-4}

  SNP           GWAS End point   Coded/Non Coded Allele   GWAS Effect[\*](#nt105){ref-type="table-fn"}   Minor Allele (Frequency)   Odds ratio \[95% CI\][\*](#nt105){ref-type="table-fn"}   *P* value   *P* value Interaction^†^       Gene
  ------------ ---------------- ------------------------ ---------------------------------------------- -------------------------- -------------------------------------------------------- ----------- -------------------------- ---------------
  rs223116            RR                  A/G                                 Dec                                A (0.24)                                                                                                           *THTPA-NGDN-*
  LAD                                                                                                                                               0.86 \[0.64 -- 1.17\]                      0.340              0.0163             *ZFHX-MYH7*
  LCX                                                                                                                                               2.08 \[1.04 -- 4.17\]                      0.039                               
  RCA                                                                                                                                               1.61 \[1.03 -- 2.51\]                      0.037                               
  rs281868            RR                  G/A                                 Dec                                A (0.49)                           0.99 \[0.81 -- 1.21\]                      0.929              0.237               *SLC35F1*
  rs6795970           PR                  A/G                                 Inc                                A (0.39)                           0.77 \[0.63 -- 0.94\]                      0.009              0.897               *SCN10A*
  rs11708996      PR≥200 ms               C/G                                 Inc                                C (0.16)                           1.24 \[0.93 -- 1.65\]                      0.144              0.235                *SCN5A*
  rs1886512          QRS                  A/T                                 Dec                                A (0.37)                           0.98 \[0.80 -- 1.20\]                      0.824              0.549                *KLF12*
  rs883079           QRS                  C/T                                 Inc                                C (0.26)                           0.90 \[0.72 -- 1.13\]                      0.359              0.819                *TBX5*
  rs17779747         QTc                  T/G                                 Dec                                T (0.34)                           1.27 \[1.03 -- 1.57\]                      0.026              0.921                *KCNJ2*
  rs8049607          QTc                  T/C                                 Inc                                C (0.49)                           1.05 \[0.87 -- 1.29\]                      0.597              0.942                *LITAF*

effect estimate is given per copy of the coded allele adjusted for age, sex and culprit artery. † *P* values for interaction between SNPs and culprit artery on risk of VF

Discussion {#s4}
==========

In the current study, we confirm and extend previous observations that heart rate and ECG indices of conduction and repolarization differ between acute STEMI patients who develop VF and acute STEMI patients who do not develop VF. Although our analysis only detected nominal association with the STEMI ECG traits for only a minority of SNPs, the effect size and direction for the association of these SNPs was comparable to that found for the corresponding trait in the general population. Furthermore, of the eight SNPs displaying such association, three also displayed a trend for association with VF.

Ischemic ECG indices and VF {#s4a}
---------------------------

Ischemic ECGs of patients with VF (cases) showed, on average, shorter RR intervals, longer QTc intervals and more ST segment deviation than patients without VF (controls). When the culprit artery harbouring the occluding lesion was taken into account, cases with an LCX occlusion had a longer QRS duration. This finding is similar to our previous findings in a smaller sample of STEMI patients with and without VF [@pone.0057216-Lemmert1]. However, the observation in this previous study of longer QRS interval in cases with an RCA occlusion was not observed in the present study. With respect to QTc interval, cases with either an LAD or LCX occlusion had a longer QTc-interval compared to controls. This extends our earlier findings, where similar (though non-significant) differences in QTc interval were found for the same culprit arteries. The observed longer QRS duration and QTc interval in cases with VF reflect cardiac conduction delay and prolonged repolarization time, respectively, consistent with a more pro-arrhythmic substrate in cases [@pone.0057216-Zareba1].

ECG candidate SNPs, STEMI ECG indices and VF {#s4b}
--------------------------------------------

Recent GWAS have identified multiple common genetic variants affecting heart rate, conduction and repolarization in individuals from the general population [@pone.0057216-Chambers1]--[@pone.0057216-Eijgelsheim1]. However, whether these variants also influence ECG indices in the setting of STEMI has not yet been investigated. In our study, none of the association P-values exceeded our stringent pre-set threshold for statistical significance. Eight SNPs displayed a suggestive association to the corresponding STEMI ECG parameter, and of note all eight SNPs displayed an effect that was similar in direction and magnitude to that observed in the general population [@pone.0057216-Chambers1]--[@pone.0057216-Eijgelsheim1]. However our findings also demonstrate that SNPs which are known to exert only small effects on ECG parameters in the general population, do not have a markedly increased effect on ECG indices in the setting of acute STEMI.

None of the eight SNPs that displayed nominal association with STEMI ECG parameters passed our stage 2 Bonferroni threshold (*P*\<0.0063) for the association with VF. However, as previously reported [@pone.0057216-Chambers1], the A-allele of rs6795970 in the *SCN10A* gene appears to be associated with a decreased risk of VF in the AGNES population (*P* = 0.009). The rs6795970 SNP has consistently been shown to impact on PR interval in different studies carried out in the general population [@pone.0057216-Chambers1]--[@pone.0057216-Holm1], with the A-allele being the PR-prolonging allele. We now show that this SNP may also be associated with a longer PR interval during acute STEMI. In addition to PR interval, rs6795970 has been found associated with QRS in GWA studies, underscoring the shared molecular underpinning of atrio-ventricular and ventricular conduction. In spite of this, the effect of rs6795970 on QRS duration in our study was small and non-significant. SNP rs6795970 is in high LD (r^2^ = 0.93) with rs6801957 with both SNPs being localized within the *SCN10A* gene located immediately downstream of *SCN5A* on chromosome 3. SNP rs6801957 is located in a T-box transcription factor binding motif within an enhancer element and the PR- and QRS-prolonging minor allele of this SNP was recently shown to affect TBX3/TBX5 binding and T-box factor response of the enhancer [@pone.0057216-VandenBoogaard1]. These recent findings suggest that rs6801957 is the causal SNP and that this SNP may modulate *SCN5A* and / or *SCN10A* expression levels in human heart and thereby impact on conduction and arrhythmia risk.

The common genetic variants identified to date as modulators of ECG indices in the general population all carry very small effect sizes and even when considered in aggregate, explain only a very small percentage of the variation in these indices. For instance, in a meta-analysis for identification of QTc-associating SNPs by Pfeufer and co-workers [@pone.0057216-Pfeufer2], SNPs at 10 different loci in aggregate explained only around 3% of the variance in this trait. The effects of these common genetic variants on the STEMI ECG are small and insufficient to explain the differences found in STEMI ECGs of cases and controls. This underscores the need for further studies aimed at uncovering additional genetic variants, such as rare variants associated with larger effects, which would lead to a more-complete representation of the allelic architecture of these differences in STEMI ECGs.

Strengths and Limitations {#s4c}
-------------------------

In this study, we had the unique opportunity to study the effect of genetic variants, known to impact on ECG indices in the general population, on VF in a well-defined case-control set of patients with a first acute STEMI. Our study is rather unique in that the availability of STEMI ECGs and DNA from patients in whom STEMI is complicated by VF is very scarce due to the high mortality in these patients. On the other hand, as a consequence, our sample size is limited, which can result in insufficient statistical power. Furthermore, the STEMI ECGs used in this study were retrieved retrospectively and, therefore, the time between the onset of complaints and acquisition of the STEMI ECG varied among the study participants. Also since the ECGs were retrieved retrospectively, some were of insufficient quality for analysis, limiting the size of the sample available for analysis. The first recorded ECG that was acquired during STEMI and before reperfusion treatment was used for this analysis. Due to the nature of this complex and specific phenotype under investigation a resting ECG without STEMI prior to the index event is missing for most of the patients and the effects of SNPs on baseline ECGs from these patients could, therefore, not be tested. Our analysis did not account for effects which may arise from differences in infarct size, intake of amiodarone or cardioversion. However, with respect to infarct size, additional adjustment for peak CKMB as a marker of infarct size, resulted in similar effect estimates but with larger confidence intervals, mainly related to the reduced sample size as peak CKMB was not available in all patients (**[Table S1](#pone.0057216.s001){ref-type="supplementary-material"}**).

Conclusion {#s5}
==========

In conclusion, ECG indices of conduction and repolarization differ between STEMI patients with VF and STEMI patients who do not develop VF. Although the effects of some SNPs on ECG parameters during an acute STEMI were similar in magnitude and direction as those found in the general population, the effects were too small to explain the differences in conduction and repolarization indices and to exert any marked impact on risk of VF. Nevertheless, rs6795970, located within the *SCN10A* gene, associated with longer PR interval in the general population and with longer PR interval and risk of VF during STEMI in our study, merits investigation in future larger studies.
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